Liu Liyun, Li Shuiqin, Wu Yongcan, Wang Xiaomin, Huang Demei, Pei Caixia, Wang Fei, Wang Zhenxing
School of basic medical sciences, Chengdu University of Traditional Chinese Medicine, No. 1166 Liutai avenue, Wenjiang district.
Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, Sichuan Province, People's Republic of China.
Medicine (Baltimore). 2020 Jul 10;99(28):e20692. doi: 10.1097/MD.0000000000020692.
The key to the management of chronic obstructive (CB) and chronic obstructive pulmonary disease (COPD) is to control symptoms of the disease and to prevent deterioration in the health of affected patients. Myrtol has been proved to be effective in treating the symptoms of patients with CB and COPD and preventing the deterioration in their health. However, there has been no systematic review of the efficacy and safety of myrtol in the treatment of CB or COPD. The purpose of this study is going to evaluate the effects of myrtol on the management of CB or COPD based on randomized controlled trials.
Electronic literature and other ongoing studies will be searched before November 31, 2019. Randomized controlled trials that report the use of myrtol in the treatment of CB or COPD (in the absence and presence of concurrent treatments) will be selected for inclusion regardless of language. Primary outcomes will include cumulative numbers of exacerbation events and the number of days of disability including days in bed, days off work due to breathing complications, and days on which the participant was unable to undertake normal activities due to breathing complications. Study selection, data extraction, and deviation the derivation risk assessment will be carried out by 2 independent investigators. Meta-analysis will be carried out by the RevMan5.3 software.
The study will provide summary results for estimating the efficacy and safety of myrtol for future treatments of CB or COPD.
This systematic review will determine if myrtol is an effective and a safe intervention on the symptoms and the prevention of exacerbation of CB or COPD.
Ethical approval will not be required for this study because no identifying patient data will be used. The review will be published as an article or a conference presentation in a peer-reviewed journal.
OSF registration number: DOI 10.17605/OSF.IO/PXRBV.
慢性支气管炎(CB)和慢性阻塞性肺疾病(COPD)管理的关键在于控制疾病症状并预防受影响患者健康状况恶化。已证实桃金娘油在治疗CB和COPD患者症状及预防其健康状况恶化方面有效。然而,尚未对桃金娘油治疗CB或COPD的疗效和安全性进行系统评价。本研究的目的是基于随机对照试验评估桃金娘油对CB或COPD管理的效果。
将检索截至2019年11月31日的电子文献及其他正在进行的研究。将纳入报告使用桃金娘油治疗CB或COPD(无论有无联合治疗)的随机对照试验,不限语言。主要结局将包括急性加重事件的累积数量以及残疾天数,包括卧床天数、因呼吸并发症误工天数以及参与者因呼吸并发症无法进行正常活动的天数。研究筛选、数据提取和偏倚风险评估将由2名独立研究者进行。将使用RevMan5.3软件进行荟萃分析。
本研究将提供总结结果,以评估桃金娘油在未来治疗CB或COPD中的疗效和安全性。
本系统评价将确定桃金娘油对CB或COPD症状及预防急性加重是否为有效且安全的干预措施。
本研究无需伦理批准,因为不会使用可识别患者的数据。该评价将作为一篇文章或在同行评审期刊上的会议报告发表。
开放科学框架(OSF)注册号:DOI 10.17605/OSF.IO/PXRBV 。